Praxis Precision Medicines Inc (PRAX) Stock Analysis

Praxis Precision Medicines Inc (PRAX) is a publicly traded company in the HEALTHCARE sector. It trades at $258.08, carries a market capitalization of $9.34B. This page summarizes the public market data, fundamentals, and frequently asked questions for PRAX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Praxis Precision Medicines Inc currently has a Neutral sentiment score of 0.09.

About Praxis Precision Medicines Inc

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, dedicated to developing innovative therapies for central nervous system disorders linked to neuronal imbalance. Utilizing a proprietary scientific platform, Praxis aims to identify and advance novel treatments for a range of neurological conditions, prioritizing those with significant unmet medical needs. With a strong pipeline and a commitment to enhancing patient outcome...

GNG Research Analysis

GNG Research scores Praxis Precision Medicines Inc (PRAX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for PRAX.

Frequently Asked Questions

Does PRAX pay dividends?

Praxis Precision Medicines Inc (PRAX) does not currently pay a regular dividend.

What is PRAX's market cap?

Praxis Precision Medicines Inc (PRAX) has a market capitalization of $9.34B with a current stock price of $258.08.